Glaxo's Trelegy Ellipta gets EU approval for treatment of COPD

GlaxoSmithKline and Innoviva have been granted marketing authorisation by the European Commission for their Trelegy Ellipta once-daily single inhaler triple therapy for the treatment of adult patients with moderate to severe chronic obstructive pulmonary disease.

FTSE 100

8,109.32

16:35 18/11/24

n/a

FTSE 350

4,473.50

17:09 18/11/24

n/a

FTSE All-Share

4,431.13

16:49 18/11/24

n/a

GSK

1,310.00p

16:40 18/11/24

0.69%

9.00p

Pharmaceuticals & Biotechnology

19,204.40

17:09 18/11/24

-0.28%

-53.32

Trelegy Ellipta is the first once-daily single inhaler triple therapy to be approved in Europe. It is a combination of an inhaled corticosteroid, a long-acting muscarinic antagonist and a long-acting beta2-adrenergic agonist, delivered once daily in GSK's Ellipta dry powder inhaler.

Eric Dube, senior vice president & head of the GSK Global Respiratory Franchise said: "COPD is a serious lung disease that affects millions of people. Its progressive nature means symptoms can worsen over time with many patients also experiencing frequent debilitating exacerbations.

“A combination of different types of medicines can be required to achieve treatment goals. Trelegy Ellipta is the first medicine to be approved in Europe that delivers three effective molecules in a once-daily single inhalation. We believe this is an important innovation in COPD management and look forward to making it available for appropriate patients with COPD."

The Trelegy Ellipta treatment is for those who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist.